ClinicalTrials.gg
Status unknownNCT03840512Updated Sep 1, 2021

An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)

A Phase 2 interventional study of CBD in Prevention aGVHD, sponsored by Kalytera Therapeutics Israel, Ltd.. Status unknown at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by Kalytera Therapeutics Israel, Ltd. · Phase 2, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2018, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)

Read the detailed description

The study contains 3 cohorts of 12 participants each: All participants will be orally administered for 105 days with CBD at doses of 75, 150 or 300 mg (PO) BID for the prevention of acute GVHD (aGVHD) following allogeneic HSCT.

In addition to the study drug, all participants will receive standard aGVHD prophylaxis consisting of a calcineurin inhibitor (cyclosporine or tacrolimus) and a short course of methotrexate (MTX). After completion of 105 treatment days, the participant will be followed-up until day 180.

02

Conditions studied

  • Prevention aGVHD
03

In context

Lead sponsor

This is the only study on the registry with Kalytera Therapeutics Israel, Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any malignant hematological disease in CR or Myelodysplastic Syndrome (MDS)
  2. Age ≥ 18 years
  3. Score (KS) ≥ 60%
  4. -Comorbidity Index (HSCT-CI) score ≤ 3
  5. No major organ dysfunction
  6. Myeloablative or reduced intensity conditioning regimen
  7. Matched (7/8 or 8/8) unrelated donor
  8. Peripheral blood stem cell graft
  9. Female subjects of must use a medically accepted method of and must agree to continue use of this method for the duration of the study and for the follow-up time period. Acceptable methods of contraception include abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method.
  10. Male subjects with partners of childbearing potential must agree to use adequate contraception (barrier method or abstinence) during the study.
  11. Subject's written

Exclusion criteria

Exclusion Criteria:

  1. Malignant hematological disease other than MDS, not in CR
  2. Myelofibrosis
  3. transplantation from a matched or mismatched sibling donor
  4. Cord blood transplantation
  5. Positive serology for
  6. Serious psychiatric or psychological disorders
  7. Any uncontrolled infection at time of registration
  8. Active consumption of illicit drugs (such as: Crack cocaine, Heroin, Methamphetamines, Cocaine, Bath Salts, Amphetamines, Methadone, Benzodiazepine, Ecstasy)
  9. Use of Cannabis and/or its derivatives fourteen days prior to HSCT and for the duration of study participation
  10. Uncontrolled or active infection.
  11. >450ms per Fridericia's correction and Impaired cardiac function or cardiac diseases
  12. Inadequate renal function defined as measured > 2.0 mg/dl
  13. Liver enzymes: and AST > 3x
  14. Pregnancy or breastfeeding ((positive serum β-HCG 7 days before first dose)
  15. Treatment with another drug, biological agent, or device within 30 days of first dose, or investigational cell therapy within 6 months of first dose
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Oral CBD 75 BID

    Drug: CBD

  • Experimental
    Oral CBD 150 BID

    Drug: CBD

  • Experimental
    Oral CBD 300 BID

    Drug: CBD

Interventions

  • DrugCBD

    CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX). Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs) and serious adverse events (SAEs) Reporting

    All AEs will be recorded, whether considered minor or serious, drug-related or not

    Time frame: Up to day 180

  2. Cumulative incidence of aGVHD at day 100 post-transplant

    Cumulative Incidence of Grade B-D aGvHD

    Time frame: First 100 days after transplant

  3. Pharmacokinetic parameters of Cannabidiol (CBD) - Cmax

    Pharmacokinetic (PK) profile - Cmax - Maximum Plasma Concentration

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  4. Pharmacokinetic parameters of Cannabidiol (CBD) - Tmax

    Pharmacokinetic (PK) profile - Tmax - time to reach maximum plasma concentration

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  5. Pharmacokinetic parameters of Cannabidiol (CBD) - Tlag

    Pharmacokinetic (PK) profile - Tlag - Absorption lag-time defined as the time of the first concentration ≥ Limit of Quantitation (LOQ)

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  6. Pharmacokinetic parameters of Cannabidiol (CBD) - AUC0-t

    Pharmacokinetic (PK) profile - AUC0-t - area under the plasma concentration-time curve (AUC0-t) up to the last quantifiable concentration (LOQ) from time of administration (t=0) up to the selected

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  7. Pharmacokinetic parameters of Cannabidiol (CBD) - λz

    Pharmacokinetic (PK) profile: λz - Elimination rate constant determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  8. Pharmacokinetic parameters of Cannabidiol (CBD) - T1/2

    Pharmacokinetic (PK) profile: T1/2 - Terminal elimination half-life

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  9. Pharmacokinetic parameters of Cannabidiol (CBD) - AUC0-∞

    Pharmacokinetic (PK) profile: AUC0-∞ - area under the plasma concentration-time curve extrapolated to infinity

    Time frame: Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD

  10. Cumulative incidence of aGVHD at day 180 post-transplant

    Cumulative Incidence of Grade 2-4 aGvHD

    Time frame: Day 180 post-transplant

07

Study locations

5 sites
  • St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
    Sydney, 2010, Australia
  • Rambam Health Care - Bone Marrow Transplantation Unit
    Haifa, 3109601, Israel
  • Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center
    Jerusalem, 91120, Israel
  • Davidof Cancer Center, Beilinson hospital, Rabin medical center
    Petach Tikva, 49100, Israel
  • Tel-Aviv Sourasky Medical Center - Bone Marrow Transplantation Unit
    Tel Aviv, Israel
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2018 (actual). Primary completion is estimated for Nov 2022, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2019
First posted
Feb 15, 2019
StartActual
Jun 12, 2018
Primary completionEst.
Nov 15, 2022
CompletionEst.
Dec 15, 2022
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03840512
Lead sponsor
Kalytera Therapeutics Israel, Ltd.
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Jun 12, 2018
Primary completion
Nov 15, 2022 (estimated)
Completion
Dec 15, 2022 (estimated)
Last update
Sep 1, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion